Active secretion and enterocytic drug metabolism barriers to drug absorption

Advanced Drug Delivery Reviews

Volumn 20, Issue 1, 1996, Pages 99-112

  Wacher, Vincent J ^a   Salphati, Laurent ^b   Benet, Leslie Z ^b  

^a AvMax Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Active transport; Bioavailability; Cytochrome P450 3A; Intestine; Metabolism; P glycoprotein

Indexed keywords

ABSORPTION; BIOSYNTHESIS; CELLS; DRUG INTERACTIONS; DRUG THERAPY; ENZYMES; METABOLISM; PHARMACODYNAMICS; PROTEINS; TISSUE;

ACTIVE SECRETION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLIZING ENZYME; ENTEROCYTIC DRUG METABOLISM; INHIBITOR SPECIFICITIES; INTESTINAL PHASE METABOLISM; MULTIDRUG EFFLUX PUMP; P GLYCOPROTEIN;

DRUG PRODUCTS;

AMIODARONE; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; DILTIAZEM; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; ESTRADIOL; ETOPOSIDE; FELODIPINE; GLYCOPROTEIN P; ITRACONAZOLE; KETOCONAZOLE; LIDOCAINE; MIDAZOLAM; MIFEPRISTONE; NIFEDIPINE; PACLITAXEL; PREDNISONE; PROGESTERONE; QUINIDINE; RAPAMYCIN; RIFAMPICIN; TAMOXIFEN; TERFENADINE; TESTOSTERONE; UNINDEXED DRUG;

ACTIVE TRANSPORT; ANIMAL MODEL; CELL LINE; CELL SECRETION; DIET; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; ENZYME INHIBITION; ENZYME SPECIFICITY; FOOD DRUG INTERACTION; HUMAN; HUMAN CELL; INTESTINE CELL; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN INDUCTION; REVIEW; SMALL INTESTINE;

EID: 0030581087     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00127-S     Document Type: Review

References (90)

1. [1] Aungst, B.J. (1993) Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J. Pharm. Sci. 82, 979-987.
2. [2] Ilett, K.F., Tee, L.B.G., Reeves, P.T. and Minchin, R.F. (1990) Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol. Ther. 46, 67-93.
3. [3] Tam, Y.K. (1993) Individual variation in first-pass metabolism. Clin. Pharmacokinet. 25, 300-328.
4. [4] Krishna, D.R. and Klotz, U. (1994) Extrahepatic metabolism of drugs in humans. Clin. Pharmacokinet. 26, 144-160.
5. [5] Back, D.J. and Rogers, S.M. (1987) First-pass metabolism by gastrointestinal mucosa. Aliment. Pharmacol. Ther. 1, 339-357.
6. [6] de Waziers, P.H., Cugnenc, P.H., Yang, C.S., Leroux, J.-P. and Beaune, P.H. (1990) Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253, 387-394.
7. [7] Wacher, V.J., Wu, C.-Y. and Benet L.Z. (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13, 129-134.
8. [8] Watkins, P.B. (1994) Non-invasive tests of CYP3A enzymes. Pharmacogenetics 4, 171-184.
9. [9] Watkins, P.B., Wrighton, S.A., Schuetz, E.G. and Guzelian, P.S. (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80, 1029-1036.
10. [10] Murray, G.I., Barnes, T.S., Sewell, H.F., Ewen, S.W.B., Melvin, W.T. and Burke, M.D. (1988) The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450, Br. J. Pharmacol. 25, 465-475.
11. [11] Peters, W.H.M. and Kremers, P.G. (1989) Cytochromes P-450 in the intestinal mucosa of man. Biochem. Pharmacol. 38, 1535-1538.
12. [12] Kolars, J.C., Schmiedlin-Ren, P., Schuetz, J.D., Fang, C. and Watkins, P.B. (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90, 1871-1888.
13. [13] Kolars, J.C., Lown, K.S., Schmiedlin-Ren, P., Ghosh, M., Fang, C., Wrighton, S.A., Merion, R.M. and Watkins, P.B. (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4, 247-259.
14. [14] McKinnon, R.A., Burgess, W.M., Hall, P. de la M., Roberts-Thomson, S.J., Gonzalez, F.J. and McManus, M.E. (1995) Characterization of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 36, 259-267.
15. [15] Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F.P. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 caucasians. J. Pharmacol. Exp. Ther. 270, 414-423.
16. [16] Forsyth, R.P., Nies, A.S., Wyler, F., Neutze, J. and Melmon, K.L. (1968) Normal distribution of cardiac output in the unanesthetized, restrained rhesus monkey. J. Appl. Physiol. 25, 736-741.
17. [17] Benet, L.Z., Wu, C.-Y., Hebert, M.F. and Wacher, V.J. (1996) Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J. Control. Rel. 39, 139-143.
18. [18] Levêque, D. and Jehl, F. (1995) P-glycoprotein and pharmacokinetics. Anticancer Res. 15, 331-336.
19. [19] Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I. and Willingham, M.C. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84, 7735-7738.
20. [20] McDonnell, W.M., Scheiman, J.M. and Traber, P.G. (1992) Induction of cytochrome P4501A genes by omeprazole in the human alimentary tract. Gastroenterology 103, 1509-1516.
21. [21] Buchthal, J., Grund, K.E., Buchmann, A., Schrenk, D., Beaune, P. and Bock, K.W. (1995) Induction of cytochrome P4501A by smoking or omeprazole in comparison with UDP-glucuronosyltransferase in biopsies of human duodenal mucosa. Eur. J. Clin. Pharmacol. 47, 431-435.
22. [22] Lown, K.S., Kolars, J.C., Thummel, K.E., Barnett, J.L., Kunze, K.L., Wrighton, S.A. and Watkins, P.B. (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab. Dispos. 22, 947-955.
23. [23] Wrighton, S.A., Ring, B.J., Watkins, P.B. and Vandenbranden, M. (1989) Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol. Pharmacol. 36, 97-105.
24. [24] Wrighton, S.A., Brian, W.R., Sari, M.-A., Iwasaki, M., Guengerich, F.P., Raucy, J.L., Molowa, D.T. and Vandenbranden, M. (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38, 207-13.
25. [25] Schuetz, E.G., Schuetz, J.D., Strom, S.C., Thompson, M.T., Fisher, R.A., Molowa, D.T., Li, D. and Guzelian, P.S. (1993) Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology 18, 1254-1262.
26. [26] Aoyama, T., Yamano, S., Waxman, D.J., Lapenson, D.P., Meyer, U.A., Fischer, V., Tyndale, R., Inaba, T., Kalow, W., Gelboin, H.V. and Gonzalez, F.J. (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450IIIA gene product that is differentially expressed in adult human liver. J. Biol. Chem. 264, 10388-10395.
27. [27] Gorski, J.C., Hall, S.D., Jones, D.R., Vandenbranden, M. and Wrighton, S.A. (1994) Regioselective biotransformation of midazolam by members of the cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47, 1643-1653.
28. [28] Thummel, K.E., Shen, D.D., Podoll, T.D., Kunze, K.L., Trager, W.F., Hartwell, P.S., Raisys, V.A., Marsh, C.L., McVicar, J.P., Barr, D.M., Perkins, J.D. and Carithers, R.L., Jr. (1994) Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 27, 549-556.
29. [29] Thummel, K.E., Shen, D.D., Podoll, T.D., Kunze, K.L., Trager, W.F., Bacchi, C.E., Marsh, C.L., McVicar, J.P., Barr, D.M., Perkins, J.D. and Carithers, R.L., Jr. (1994) Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J. Pharmacol. Exp. Ther. 27, 557-566.
30. [30] Watkins, P.B., Murray, S.A., Winkelman, L.G., Heuman, D.M., Wrighton, S.A. and Guzelian, P.S. (1989). Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J. Clin. Invest. 83, 688-697.
31. [31] Schuetz, E.G., Schuetz, J.D., Grogan, W.M., Naray-Fejes-Toth, A., Fejes-Toth, G., Raucy, J., Guzelian, P., Gionela, K. and Watlington, C.O. (1992) Expression of cytochrome P450 3A in amphibian, rat and human kidney. Arch. Biochem. Biophys. 294, 206-214.
32. [32] Guengerich, F.P. (1995) Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. Am. J. Clin. Nutr. 61 (suppl), 651S-658S.
33. [33] Warner, P.E., Brouwer, K.L.R., Hussey, E.K., Dukes, G.E., Heizer, W.D., Donn, K.H., Davis, I.M. and Powell J.R. (1995) Sumatriptan absorption from different regions of the human gastrointestinal tract. Pharm. Res. 12, 138-143.
34. [34] Lacey, L.F., Hussey, E.K. and Fowler, P.A. (1995) Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur. J. Clin. Pharmacol. 47, 543-548.
35. [35] Kanfer, I., Dowse, R. and Vuma, V (1993) Pharmacokinetics of oral decongestants. Pharmacotherapy 13, 116S-128S.
36. [36] Mahon, W.A., Inaba, T. and Stone, R.M. (1977) Metabolism of flurazepam by the small intestine. Clin. Pharmacol. Ther. 22, 228-233.
37. [37] Kolars, J.C., Awni, W.M., Merion, R.M. and Watkins, P.B. (1991) First-pass metabolism of cyclosporine by the gut. Lancet 338, 1488-1490.
38. [38] Thummel, K.E. (1995) Modeling hepatic and intestinal metabolism of the CYP3A probe midazolam from in vitro data. AAPS Symposium on Prediction of Metabolic Clearance, Bioavailability and Drug Interactions from In Vitro-Derived Data. AAPS Tenth Annual Meeting and Exposition. Miami Beach, FL, November 9, 1995.
39. [39] Hebert, M.F., Roberts, J.P., Prueksaritanont, T. and Benet, L.Z. (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52, 453-457.
40. [40] Gomez, D.Y., Wacher, V.J., Tomlanovich, S.J., Hebert, M.F. and Benet, L.Z. (1995) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther. 58, 15-19.
41. [41] Gupta, S.K., Bakran, A., Johnson, R.W.G. and Rowland, M. (1988) Erythromycin enhances the absorption of cyclosporine. Br. J. Clin. Pharmacol. 25, 401-402.
42. [42] Wu, C.-Y., Benet, L.Z., Hebert, M.F., Gupta, S.K., Rowland, M., Gomez, D.Y. and Wacher, V.J. (1995) Differentiation of absorption, first pass gut and hepatic metabolism in man. Studies with cyclosporine. Clin. Pharmacol. Ther. 58, 492-497.
43. [43] Gupta, S.K., Manfro, R.C., Tomlanovich, S.J., Gambertoglio, J.G., Garovoy, M.R. and Benet, L.Z. (1990) Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J. Clin. Pharmacol. 30, 643-653.
44. [44] Barnwell, S.G., Laudanski, T., Story, M.J., Mallinson, C.B., Harris, R.J., Cole, S.K., Keating, M. and Attwood, D. (1992) Improved oral bioavailability of propanolol in healthy human volunteers using a liver bypass drug delivery system containing oleic acid. Int. J. Pharm. 88, 423-432.
45. [45] Ducharme, M.P., Warbasse, L.H. and Edwards, D.J. (1995) Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. Ther. 57, 485-491.
46. [46] Kupferschmidt, H.H.T., Ha, H.R., Ziegler, W.H., Meier, P.J. and Krahenbuhl, S. (1995) Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther. 58, 20-28.
47. [47] Bailey, D.G., Spence, J.D., Munoz, C. and Arnold, J.M.O. (1991) Interaction of citrus juices with felodipine and nifedipine. Lancet 337, 268-269.
48. [48] Edgar, B., Bailey, D., Bergstrand, R., Johnsson, G. and Regårdh, C.G. (1992) Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine - and its potential clinical relevance. Eur. J. Clin. Pharmacol. 42, 313-317.
49. [49] Bailey, D.G., Arnold, J.M.O., Strong, H.A., Munoz, C. and Spence, J.D. (1993) Grapefruit juice-felodipine interaction: mechanism, predictability and effect of naringin. Clin. Pharmacol. Ther. 53, 637-642.
50. [50] Bailey, D.G., Arnold, J.M.O., Bend, J.R., Tran, L.T. and Spence, J.D. (1995) Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br. J. Clin. Pharmacol. 40, 135-140.
51. [51] Rashid, J., McKinstry, C., Renwick, A.G., Dirnhuber, M., Waller, D.G. and George, C.F. (1993) Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br. J. Clin. Pharmacol. 36, 460-463.
52. [52] Bailey, D.G., Arnold, J.M.O., Strong, H.A., Munoz, C. and Spence, J.D. (1993) Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin. Pharmacol. Ther. 54, 589-594.
53. [53] Soons, P.A., Vogels, B.A.P.M., Roosemalen, M.C.M., Schoemaker, H.C., Uchida, E., Edgar, B., Lundahl, J., Cohen, A.F. and Breimer, D.D. (1991) Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin. Pharmacol. Ther. 50, 394-403.
54. [54] Benton, R., Honig, P., Zamani, K., Hewett, J., Cantilena, L.R. and Woosley, R.L. (1994) Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of Qtc. [Abstract] Clin. Pharmacol. Ther. 55, 146.
55. [55] Yee, G.C., Stanley, D.L., Pessa, L.J., Dalla Costa, T., Beltz, S.E., Ruiz, J. and Lowenthal, D.T. (1995) Effect of grapefruit juice on blood cyclosporin concentration. Lancet 345, 955-956.
56. [56] Guengerich, F.P. and Kim, D.-H. (1990) In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11, 2275-2279.
57. [57] Miniscalco, A., Lundahl, J., Regårdh, C.G., Edgar, B. and Eriksson, U.G. (1992) Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J. Pharmacol. Exp. Ther. 261, 1195-1199.
58. [58] Proppe, D.G., Hoch, O.D., McLean, A.J. and Visser, K.E. (1995) Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function. Br. J. Clin. Pharmacol. 39, 337-338.
59. [59] Hollander, A.A.M.J., van Rooij, J., Lentjes, E.G.W.M., Arbouw, F., van Bree, J.B., Schoemaker, R.C., van Es, L.A., van der Woude, F.J. and Cohen, A.F. (1995) The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin. Pharmacol. Ther. 57, 318-324.
60. [60] Schubert, W., Cullberg, G., Edgar, B. and Hedner, T. (1995) Inhibition of 17β-estradiol metabolism in grapefruit juice in ovarectomized women. Maturitas 20, 155-163.
61. [61] Li, Y., Wang, E., Patten, C.J., Chen, L. and Yang, C.S. (1994) Effects of flavonoids on cytochrome P450-dependent acetaminophen metabolism in rats and human liver microsomes. Drug Metab. Dispos. 22, 566-571.
62. [62] Fuhr, U., Klittich, K. and Staib, A.H. (1993) Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br. J. Clin. Pharmacol. 35, 431-436.
63. [63] Merkel, U., Sigusch, H. and Hoffmann A. (1994) Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur. J. Clin. Pharmacol. 46, 175-177.
64. [64] McKinnon, R.A., Burgess, W.M., Hall, P., de la M., Abdul-Aziz, Z. and McManus, M.E. (1992) Metabolism of food-derived heterocyclic amines in human and rabbit tissues by P4503A proteins in the presence of flavonoids. Cancer Res. 52 (suppl.), 2108S-2113S.
65. [65] Castañeda-Hernández, G., Hoyo-Vadillo, C., Palma-Aguirre, J.A. and Flores-Murrieta, F.J. (1992) Pharmacokinetics of oral nifedipine in different populations. J. Clin. Pharmacol. 32, 140-145.
66. [66] Ahsan, C.H., Renwick, A.G., Macklin, B., Challenor, V.F., Waller, D.G. and George, C.F. (1991) Ethnic differences in the pharmacokinetics of oral nifedipine. Br. J. Clin. Pharmacol. 31, 399-403.
67. [67] Kovarik, J.M., Mueller, E.A., van Bree, J.B., Fluckiger, S.S., Lange, H., Schmidt, B., Boesken, W.H., Lison, A.E. and Kutz, K. (1994) Cyclosporine pharmacokinetics and variability from a microemulsion formulation - a multicenter investigation in kidney transplant patients. Transplantation 58, 658-663.
68. [68] Holt, D.W., Mueller, E.A., Kovarik, J.M., van Bree, J.B., Richard, F. and Kutz, K. (1995) Sandimmun Neoral pharmacokinetics: impact of the new oral formulation. Transplant. Proc. 27, 1434-1437.
69. [69] Kahan, B.D., Dunn, J., Fitts, C, van Buren, D., Wombolt, D., Pollak, R., Carson, R., Alexander, J.W., Choc, M., Wong, R. and Hwang, D.S. (1995) Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients with a microemulsion formulation in conjunction with fasting, low-fat meals or high-fat meals. Transplantation 59, 505-511.
70. [70] Kovarik, J.M., Vernillet, L., Mueller, E.A., Freiburghaus, R., Niederberger, W. and Kutz, K. (1994). Cyclosporine disposition and metabolite profiles in renal transplant recipients receiving a microemulsion formulation. Ther. Drug Monit. 16, 519-525.
71. [71] Juliano, R.L. and Ling, V. (1976) A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152-162.
72. [72] Chin, K.V., Pastan, I. and Gottesman, M.M. (1993) Function and regulation of the human multidrug resistance gene. Adv. Cancer Res. 60, 157-179.
73. [73] Cordon-Cardo, C., O'Brien, J.P., Boccia, J., Casals, D., Bertino, J.R. and Melamed, M.R. (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38, 1277-1287.
74. [74] Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C., te Riele, H.P.J., Berns, A.J.M. and Borst, P. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502.
75. [75] Ueda, K., Okamura, N., Tanigwara, Y., Saeki, T., Kioka, N., Komano, T. and Hori, R. (1992) Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone. J. Biol. Chem. 267, 24248-24252.
76. [76] Burton, P.S., Conradi, R.A., Hilgers, A.R. and Ho, N.F.H. (1993) Evidence for a polarized efflux for peptides in the apical membrane of Caco-2 cells. Biochem. Biophys. Res. Commun. 190, 760-766.
77. [77] Gottesman, M.M. and Pastan, I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385-427.
78. [78] Zhao, J.-Y., Ikeguchi, M., Eckersberg, T. and Kuo, M.T. (1993) Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology 133, 521-528.
79. [79] Schuetz, E.G., Beck, W.T. and Schuetz, J.D. (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately upregulate these proteins in human colon carcinoma cell. Mol. Pharmacol. 49, 311-318.
80. [80] Leu, B.-L. and Huang, J.-D. (1995) Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother. Pharmacol. 35, 432-436.
81. [81] Hunter, J., Hirst, B.H. and Simmons, N.L. (1993) Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 10, 743-749.
82. [82] Hunter, J., Jepson, M.A., Tsuruo, T., Simmons, N.L. and Hirst, B.H. (1993) Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J. Biol. Chem. 268, 14991-14997.
83. [83] Augustijns, P.F., Bradshaw, T.P., Gan, L.S.L., Hendren, R.W. and Thakker, D.R. (1993) Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporine A transport. Biochem. Biophys. Res. Commun. 197, 360-365.
84. [84] Nerurkar, M.M., Burton, P.S. and Borchardt, R.T. (1995) The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res., in press.
85. [85] Woodcock, D.M., Linsenmeyer, M.E., Chojnowski, G., Kriegler, A.B., Nink, V., Webster, L.K. and Sawyer, W.H. (1992) Reversal of multidrug resistance by surfactants. Br. J. Cancer 66, 62-68.
86. [86] Okamura, N., Hirai, M., Tanigawara, Y., Tanaka, K., Yasuhara, M., Ueda, K., Komano, T. and Hori, R. (1993) Digoxin-cyclosporine A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney. J. Pharmacol. Exp. Ther. 266, 1614-1625.
87. [87] Huang, J.-D. and Su, S.-F. (1995) Effect of quinidine on digoxin absorption in the rat: interaction on P-glycoprotein in the small intestine. [Abstract] FASEB J. 9, A691. Huang, J.-D. and Su, S.-F. (1996) Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab. Dispos., submitted.
88. [87] Huang, J.-D. and Su, S.-F. (1995) Effect of quinidine on digoxin absorption in the rat: interaction on P-glycoprotein in the small intestine. [Abstract] FASEB J. 9, A691. Huang, J.-D. and Su, S.-F. (1996) Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab. Dispos., submitted.
89. [88] Gan, L.-S., Moseley, A., Khosla, B., Augustijns, P., Bradshaw, T., Hendren, W. and Thakker, D. (1995) Formation and polarized efflux of cyclosporin A metabolites in the in vitro Caco-2 cell culture. [Abstract] FASEB J. 9, A367.
90. [89] Charuk, J.H.M., Wong, P.Y. and Reithmeier R.A.F. (1995) Differential interaction of human renal P-glycoprotein with various metabolites and analogs of cyclosporine A. Am. J. Physiol. 269, F31-F39.